500660 logo

GlaxoSmithKline Pharmaceuticals Limited Stock Price

BSE:500660 Community·₹463.3b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

500660 Share Price Performance

₹2,735.10
122.95 (4.71%)
₹2,735.10
122.95 (4.71%)
Price ₹2,735.10

500660 Community Narratives

There are no narratives available yet.

Recent 500660 News & Updates

GlaxoSmithKline Pharmaceuticals Limited Key Details

₹37.4b

Revenue

₹14.1b

Cost of Revenue

₹23.3b

Gross Profit

₹13.8b

Other Expenses

₹9.5b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 06, 2025
Earnings per share (EPS)
56.09
Gross Margin
62.40%
Net Profit Margin
25.41%
Debt/Equity Ratio
0.5%

GlaxoSmithKline Pharmaceuticals Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Outstanding track record with flawless balance sheet and pays a dividend.

1 Risk
2 Rewards

About 500660

Founded
1924
Employees
3113
CEO
Bhushan Akshikar
WebsiteView website
india-pharma.gsk.com

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states in adult patients; Flutivate, a skin cream for adults, children and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is based in Mumbai, India.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Indian Market Performance

  • 7 Days: 1.5%
  • 3 Months: -1.7%
  • 1 Year: -4.7%
  • Year to Date: 0.7%
The market has climbed 1.5% in the last 7 days, lead by the Financials sector with a gain of 2.3%. Over the past year the market is down 4.7%. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›